SERASera Prognostics Inc
$1.97
$0.09
(4.37%)
Closed $1.97
$0.04
(2.03%)
After Hours
EarningsAug 5
Mkt Cap$77.14M
Vol15,857.00
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM Test-GUIDED CARE
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM Test-GUIDED CARE PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM Test-GUIDED CARE PR Newswire SALT LAKE CITY, July 9, 2026...
PR Newswire
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS PR Newswire SALT LAKE CITY, June 30, 2026 SALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company...
PR Newswire
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH PR Newswire SALT LAKE CITY, June 24, 2026 SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera...
PR Newswire
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY PR Newswire SALT LAKE CITY, June 23, 2026 --Aligns With Growing Focus on Early Identification...
PR Newswire
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy
Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION PR Newswire SALT LAKE CITY, June 1, 2026 SALT LAKE CITY, June 1, 2026 /PRNewswire/ --Sera Prognostics Inc., The Pregnancy Company (Nasdaq: SERA), focused on improving maternal and neonatal health by providing...
PR Newswire
Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Sera Prognostics (NASDAQ:SERA - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat
Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates
Sera Prognostics (SERA) delivered earnings and revenue surprises of -6.25% and -90.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS PR Newswire SALT LAKE CITY, May 6, 2026 SALT LAKE CITY, May 6, 2026...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest SERA News
ViewPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM Test-GUIDED CARE
PR Newswire
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
PR Newswire
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
PR Newswire
Advertisement|Remove ads.